Apparent diffusion coefficient histogram analysis for prediction of prognosis in glioblastoma

被引:22
作者
Kondo, Masatoshi [1 ]
Uchiyama, Yoshikazu [2 ]
机构
[1] Kumamoto Univ, Grad Sch Hlth Sci, Kuhonji 4-24-1, Kumamoto 8600976, Japan
[2] Kumamoto Univ, Fac Life Sci, Dept Med Phys, Kuhonji 4-24-1, Kumamoto 8600976, Japan
关键词
Glioblastoma; Apparent diffusion coefficient; Histogram analysis; Progression-free survival; MGMT PROMOTER METHYLATION; TEMOZOLOMIDE; BEVACIZUMAB; HETEROGENEITY; MULTICENTER; RADIATION; ERLOTINIB; SURVIVAL;
D O I
10.1016/j.neurad.2017.11.011
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background. - To investigate the potential to predict prognosis of glioblastoma (GBM) patients by analysis of the broader and lower values in the lower distribution of apparent diffusion coefficient (ADC(L)) (B&L-ADC(L)) values in the ADC histogram. Background. - Presurgical publicly available diffusion-weighted images (DWI) and contrast-enhanced T1-weighted images from 76 GBM patients were analyzed. With applied 2-mixture normal distribution in the ADC histogram of enhanced lesions on T1-weighted images, the mean and width of ADC(L) were analyzed. We dichotomized the lower mean of ADC(L) (L-ADC(L)) and the broader width of ADC L (B-ADC(L)) at their own average. B&L-ADC(L) was defined as B-ADC(L) with L-ADC(L). Progression-free survival (PFS) and overall survival (OS) were determined by using Cox proportional hazards analysis and the Kaplan-Meier method with the log-rank test. The difference between PFS and OS was calculated. Results. - Six (7.89%) patients had B&L-ADC(L) values. B&L-ADC(L) was strongly associated with poor PFS (hazard risk: 5.747; P = 0.002) and OS (hazard risk: 3.331; P = 0.018). There were significant differences in PFS (median, 77 vs. 302 days; P < 0.001) and OS (median, 199 vs. 472 days; P = 0.004) between the patents with and without B&L-ADC(L). There was no significant difference in the OS-PFS duration difference between the patients with (median, 79 days) and without B&L-ADC(L) (median, 132 days) (P = 0.348). Conclusion. - In this study, B&L-ADC(L) from pretreatment ADC analysis predicted poor PFS. B&L-ADC(L) may indicate higher cellularity and heterogeneity in GBM tumor tissue. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:236 / 241
页数:6
相关论文
共 23 条
[1]   Tumour heterogeneity in the clinic [J].
Bedard, Philippe L. ;
Hansen, Aaron R. ;
Ratain, Mark J. ;
Siu, Lillian L. .
NATURE, 2013, 501 (7467) :355-364
[2]   The Somatic Genomic Landscape of Glioblastoma [J].
Brennan, Cameron W. ;
Verhaak, Roel G. W. ;
McKenna, Aaron ;
Campos, Benito ;
Noushmehr, Houtan ;
Salama, Sofie R. ;
Zheng, Siyuan ;
Chakravarty, Debyani ;
Sanborn, J. Zachary ;
Berman, Samuel H. ;
Beroukhim, Rameen ;
Bernard, Brady ;
Wu, Chang-Jiun ;
Genovese, Giannicola ;
Shmulevich, Ilya ;
Barnholtz-Sloan, Jill ;
Zou, Lihua ;
Vegesna, Rahulsimham ;
Shukla, Sachet A. ;
Ciriello, Giovanni ;
Yung, W. K. ;
Zhang, Wei ;
Sougnez, Carrie ;
Mikkelsen, Tom ;
Aldape, Kenneth ;
Bigner, Darell D. ;
Van Meir, Erwin G. ;
Prados, Michael ;
Sloan, Andrew ;
Black, Keith L. ;
Eschbacher, Jennifer ;
Finocchiaro, Gaetano ;
Friedman, William ;
Andrews, David W. ;
Guha, Abhijit ;
Iacocca, Mary ;
O'Neill, Brian P. ;
Foltz, Greg ;
Myers, Jerome ;
Weisenberger, Daniel J. ;
Penny, Robert ;
Kucherlapati, Raju ;
Perou, Charles M. ;
Hayes, D. Neil ;
Gibbs, Richard ;
Marra, Marco ;
Mills, Gordon B. ;
Lander, Eric ;
Spellman, Paul ;
Wilson, Richard .
CELL, 2013, 155 (02) :462-477
[3]  
Cha S, 2006, AM J NEURORADIOL, V27, P475
[4]   Incremental Prognostic Value of ADC Histogram Analysis over MGMT Promoter Methylation Status in Patients with Glioblastoma [J].
Choi, Yoon Seong ;
Ahn, Sung Soo ;
Kim, Dong Wook ;
Chang, Jong Hee ;
Kang, Seok-Gu ;
Kim, Eui Hyun ;
Kim, Se Hoon ;
Rim, Tyler Hyungtaek ;
Lee, Seung-Koo .
RADIOLOGY, 2016, 281 (01) :175-184
[5]   A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma [J].
Clarke, Jennifer L. ;
Molinaro, Annette M. ;
Phillips, Joanna J. ;
Butowski, Nicholas A. ;
Chang, Susan M. ;
Perry, Arie ;
Costello, Joseph F. ;
DeSilva, Ashley A. ;
Rabbitt, Jane E. ;
Prados, Michael D. .
NEURO-ONCOLOGY, 2014, 16 (07) :984-990
[6]   OPINION Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma [J].
Furnari, Frank B. ;
Cloughesy, Timothy F. ;
Cavenee, Webster K. ;
Mischel, Paul S. .
NATURE REVIEWS CANCER, 2015, 15 (05) :302-310
[7]   MR Imaging Predictors of Molecular Profile and Survival: Multi-institutional Study of the TCGA Glioblastoma Data Set [J].
Gutman, David A. ;
Cooper, Lee A. D. ;
Hwang, Scott N. ;
Holder, Chad A. ;
Gao, JingJing ;
Aurora, Tarun D. ;
Dunn, William D., Jr. ;
Scarpace, Lisa ;
Mikkelsen, Tom ;
Jain, Rajan ;
Wintermark, Max ;
Jilwan, Manal ;
Raghavan, Prashant ;
Huang, Erich ;
Clifford, Robert J. ;
Mongkolwat, Pattanasak ;
Kleper, Vladimir ;
Freymann, John ;
Kirby, Justin ;
Zinn, Pascal O. ;
Moreno, Carlos S. ;
Jaffe, Carl ;
Colen, Rivka ;
Rubin, Daniel L. ;
Saltz, Joel ;
Flanders, Adam ;
Brat, Daniel J. .
RADIOLOGY, 2013, 267 (02) :560-569
[8]   MGMT gene silencing and benefit from temozolomide in glioblastoma [J].
Hegi, ME ;
Diserens, A ;
Gorlia, T ;
Hamou, M ;
de Tribolet, N ;
Weller, M ;
Kros, JM ;
Hainfellner, JA ;
Mason, W ;
Mariani, L ;
Bromberg, JEC ;
Hau, P ;
Mirimanoff, RO ;
Cairncross, JG ;
Janzer, RC ;
Stupp, R .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :997-1003
[9]  
Hempel M, 2017, J NEURORADIOL
[10]   Radiological features of cerebellar glioblastoma [J].
Kikuchi, Keiichi ;
Hiratsuka, Yoshiyasu ;
Kohno, Shohei ;
Ohue, Shiro ;
Miki, Hitoshi ;
Mochizuki, Teruhito .
JOURNAL OF NEURORADIOLOGY, 2016, 43 (04) :260-265